Chordae Tendineae Rupture in the United States: Trends of Outcomes, Costs and Surgical Interventions
Objectives: To describe national trends in the incidence and outcomes of patients with chordae tendineae
Methods: Patients who were diagnosed with CTR between 2000 and 2012 were identified in National (Nationwide) Inpatient Sample (NIS) registry. CTR was defined using validated International Classification of Diseases, 9th Edition, Clinical Modification diagnosis (ICD9-CM) codes.
Results: A total of 37,287 (14,833 mitral valve repair, 7780 mitral valve replacement) CTR cases were identified. Overall, in-hospital mortality in CTR decreased by 3% from 2000 to 2012 (P < 0.001). From 2000 to 2012, the rate of mitral valve repair increased from 27.2% to 46.4%, (P < 0.001) with a concurrent decrease in the rate of mitral valve replacement (from 27.8 to 17.7%, P < 0.001). After multivariate adjustment, patient age (OR = 1.04, 95% CI 1.03-1.06, P < 0.001), congestive heart failure (CHF) (OR = 2.08, 95% CI 1.19-3.64, P = 0.01), myocardial infarction (MI) (OR = 3.58, 95% CI 2.10-6.11, P < 0.001), Deyo/Charlson comorbidity index (OR = 1.23, 95% CI 1.07-1.41, P < 0.003) and use of the intra aortic balloon pump (IABP) (OR = 4.81 95% CI 2.71-8.55, P < 0.001) were found to be independently associated with greater odds of mortality in these patients. Additionally, mitral valve replacement was significantly associated with higher costs of hospitalization (coefficient 15693, 95% CI 12638-18749, P < 0.001)
Conclusion: Mitral valve repair is associated with reduced inpatient mortality and costs compared with mitral valve replacement. A substantial increase in the percentage of cases undergoing mitral valve repair with a concurrent decrease in cases undergoing mitral valve replacement were observed. Increasing age and comorbidity index, history of CHF and MI, and use of IABP were identified as factors that could increase the risk of mortality in patients with CTR.
Al-Khatib SM, Lucas FL, Jollis JG, et al. 2005. The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol 46:1536-1540.
Badhwar V, Peterson ED, Jacobs JP, et al. 2012. Longitudinal outcome of isolated mitral repair in older patients: results from 14,604 procedures performed from 1991 to 2007. Ann Thorac Surg 94:1870-1877; discussion 1877-1879.
Bhavnani SP, Coleman CI, Guertin D, et al. 2013. Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients. Ann Noninvasive Electrocardiol 18:379-388.
Dal-Bianco JP, Beaudoin J, Handschumacher MD, et al. 2014. Basic mechanisms of mitral regurgitation. Can J Cardiol 30:971-981.
Deyo RA, Cherkin DC, Ciol MA. 1992. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619.
Gabbay U, Yosefy C. 2010. The underlying causes of chordae tendinae rupture: a systematic review. Int J Cardiol 143:113-118.
Gammie JS, Sheng S, Griffith BP, et al. 2009. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 87:1431-1437; discussion 1437-1439.
Global Burden of Disease Study 2013 Collaborators. 2015. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743-800.
Kazui T, Kawazoe K. 2004. Acute mitral valve insufficiency caused by chordae rupture. Kyobu geka 57:656-662.
Kilic A, Grimm JC, Magruder JT, et al. 2015. Trends, clinical outcomes, and cost implications of mitral valve repair versus replacement, concomitant with aortic valve replacement. J Thorac Cardiovasc Surg 149:1614-1619.
Leon BM, Maddox TM. 2015. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 6:1246-1258.
Lu KJ, Kearney LG, Ord M, et al. 2013. Age adjusted Charlson Co-morbidity Index is an independent predictor of mortality over long-term follow-up in infective endocarditis. Int J Cardiol 168:5243-5248.
Mamas MA, Fath-Ordoubadi F, Danzi GB, et al. 2015. Prevalence and Impact of Co-morbidity Burden as Defined by the Charlson Co-morbidity Index on 30-Day and 1- and 5-Year Outcomes After Coronary Stent Implantation (from the Nobori-2 Study). Am J Cardiol 116:364-371.
McNeely CA, Vassileva CM. 2015. Long-term outcomes of mitral valve repair versus replacement for degenerative disease: a systematic review. Curr Cardiol Rev 11:157-162.
Rankin JS, Orozco RE, Addai TR, et al. 2004. Several new considerations in mitral valve repair. J Heart Valve Dis 13:399-409.
Samiei N, Hakimi MR, Mirmesdagh Y, et al. 2014. Surgical outcomes of heart valves replacement: A study of tertiary specialied cardiac center. ARYA Atheroscler 10:233-237.
Steiner C, Elixhauser A, Schnaier J. 2002. The healthcare cost and utilization project: an overview. Eff Clin Pract 5:143-151.
Thompson CR, Buller CE, Sleeper LA, et al. 2000. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 36(3 Suppl A):1104-1109.
Triantafyllis AS, Kortlandt F, Bakker AL, et al. 2016. Long-term survival and preprocedural predictors of mortality in high surgical risk patients undergoing percutaneous mitral valve repair. Catheter Cardiovasc Interv 87:467-75.
Vassileva CM, Shabosky J, Boley T, et al. 2012. Cost analysis of isolated mitral valve surgery in the United States. Ann Thorac Surg 94:1429-1436.